Yoğun Bakım ve Covid-19

Team NCPERE. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China. China CDC Weekly. 2020;2(8):113-22.

Guan WJ, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine,2020 Apr 30;382(18):1708-1720. Doi: 10.1056/NEJMoa2002032.

Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Intensive care management of coronavirus disease 2019(COVID-19): challenges and recommendations. Lancet Respiratory Medicine,2020 May;8(5):506-517. Doi: 10.1016/S2213-2600(20)30161-2.

Wu Z, McGoogan JM.Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA,2020 Apr 7;323(13):1239-1242. Doi: 10.1001/jama.2020.2648.

Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032PubMedGoogle ScholarCrossref

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.doi:10.1016/S0140-6736(20)30183-5PubMedGoogle ScholarCrossref

Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi:10.1001/jama.2020.1585ArticlePubMedGoogle Scholar

Scaravilli V, Grasselli G, Castagna L, Zanella A, Isgro S, Lucchini A, et al. Prone positioning improves oxygenation in spontaneously breathing nonintubated patients with hypoxemic acute respiratory failure: a retrospective study. J Crit Care. 2015;30:1390-4.

Iwashyna TJ, Boehman A, Capecelatro J, et al. Aerosol production across oxygen delivery devices in spontaneously breathing human subjects. medRxiv. [Preprint]. https://www.medrxiv.org/content/10.1101/2020.04.15.20066688v1; April 20, 2020. Accessed July 26, 2020.

Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One,2012;7(4):e35797. Doi: 10.1371/journal.pone.0035797.

Suhail Raoof, MD, Master FCCP; Stefano Nava, MD; Charles Carpati, MD; and Nicholas S. Hill, MD High-Flow, Noninvasive Ventilation and Awake (Nonintubation) Proning in Patients With Coronavirus Disease 2019 With Respiratory Failure. CHEST-26 September 2020-2441 DOI:https://doi.org/10.1016/j.chest.2020.07.013

Tobin M. Basing respiratory management of coronavirus on physiological principles. Am J Respir Crit Care Med, 2020;201(11):1319-1320.Doi: 10.1164/rccm.202004-1076ED.

Baldi E, Sechi GM, Mare C,Canevari F, Brancaglione A, PrimiR, et al. Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy. N Engl J Med. 2020;382:1708–1720. Doi: 10.1056/NEJMc2010418.

Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high flow therapy. Am J Respir Crit Care Med. 2019 Jun 1;199(11):1368-1376. Doi:10.1164/rccm.201803-0589OC.

Wax RS, Christian MD. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Canadian Journal of Anaesthesia. 2020 May;67(5):568-576. Doi: 10.1007/s12630-020-01591-x.

Pfeifer M, Ewig S, Voshaar T,Randerath W, Bauer T, Geiseler J, et al. Positionspapier zur praktischen Umsetzung der apparativen Differenzialtherapie der akuten respiratorischen Insuffizienz bei COVID-19. Pnömoloji2020 Jun;74(6):337-357. Doi: 10.1055/a-1157-9976.

Gattinoni L, Chiumello D, Caironi P,Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes?. Intensive Care Med,2020 Jun;46(6):1099-1102. Doi: 10.1007/s00134-020-06033-2.

Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA,2020 Jun 9;323(22):2329-2330. Doi: 10.1001/jama.2020.6825.

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laengeret F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med,2020 Jul 9;383(2):120-128. Doi: 10.1056/NEJMoa2015432.

Edler C, Schröder AS, Aepfelbacher M, Fitzek A, Heinemann A, Heinrich F, et al. Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Legal Med,2020 Jul;134(4):1275-1284. Doi: 10.1007/s00414-020-02317-w.

Fichtner F, Moerer O, Laudi S, Weber-Carstens S, Nothacker M, Kaisers U. Clinical practice guideline: mechanical ventilation and extracorporeal membrane oxygenation in acute respiratory insufficiency. Dtsch Arztebl Int,2018 Dec 14;115(50):840-847. Doi: 10.3238/arztebl.2018.0840.

Westhoff M, Schönhofer B, Neumann P, Bickenbach J, Barchfeld T, Beckervd H, et al.Nicht-invasive Beatmung als Therapie der akuten respiratorischen Insuffizienz. Pneumologie, 2015 Dec;69(12):719-756. Doi: 10.1055/s-0034-1393309.

Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med 2020; 8:e24.

Halacli B, Kaya A, Topeli A.Critically-ill COVID-19 patient. Turk J Med Sci, 2020 Apr 21;50(SI-1):585-591. Doi: 10.3906/sag-2004-122.

Tracheostomy for COVID-19: business as usual ?Brendan A. McGrath , Michael J. Brenner and Stephen J. Warrillow. British Journal of Anaesthesia, 125 (6): 867e871 (2020) doi: 10.1016/j.bja.2020.08.048 Advance Access Publication Date: 3 September 2020c

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA, 2016 Feb 23;315(8):801-10. Doi: 10.1001/jama.2016.0287.

Lin HY. The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy. Chin J Traumatol, 2020 Aug;23(4):190-195. Doi: 10.1016/j.cjtee.2020.06.002.

Axfors C, Schmitt AM, Janiaud P, et al: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials. medRxiv. Preprint posted online October 22, 2020. doi: https://doi.org/10.1101/2020.09.16.20194571

Waleed Alhazzani, Laura Evans, Fayez Alshamsi, Morten Hylander Møller, Marlies Ostermann, Hallie C., Prescott at al: Surviving Sepsis Campaign the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update Critical Care Medicine, 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved DOI: 10.1097/CCM.0000000000004899

T.C Sağlık Bakanlığı. Covıd-19-Sars-Cov-2 Enfeksiyonu Rehberi (Bilim Kurulu Çalışması) 01.10.2020

Williamson BN, Feldmann F, Schwarz B, et al: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 2020; 585: 273–276

Horby P, Lim WS, Emberson J, Mafham M, Bell J, Landary MJ, et al. Effect of dexamethasone in hospitalized patients with COVID-19 e preliminary report. medRxiv June 22,2020. https://doi.org/10.1101/2020.06.22.20137273. preprint.

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19:a structured summary of a study protocol for a randomised controlled tria.Luis Patricio Maskin, Gabriel Leonardo Olarte, Fernando Plizas Jr, Agostina E.Velo,Maria Fernanda Lurbet,Ignacio Bonelli,Natalio D.Baredes and Pablo Oscar Rodriguez.Trials(2020) 21:743 https://doi.org/10.1186/s13063-020-04-646-y

High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia Aikaterini Papamanoli, Jeanwoo Yoo, Prabhjot Grewal, William Predun, Jessica Hotelling, Robin Jacob, Azad Mojahedi, Hal A. Skopicki, Mohamed Mansour, Luis A. Marcos, Andreas P. Kalogeropoulos . Eur J Clin Invest. 2020;00:e13458 https://doi.org/10.1111/eci.13458

Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol, 2015;11(11):1781–1794. Doi: 10.1517/17425255.2015.1076391.

Zhou F, Yu T, Du R, Fan G, Liu Y,Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet,2020 Mar 28;395(10229):1054-1062. Doi: 10.1016/S0140-6736(20)30566-3.

Klok FA, Kruip M, Van der Meer NJM, Arbous MS, GommersD, Kantt KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19.Thromb Res, 2020 Jul;191:145-147. Doi: 10.1016/j.thromres.2020.04.013.

Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res, 2020 Jul;191:9-14. Doi: 10.1016/j.thromres.2020.04.024.

Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP,et al. Large-vessel stroke as a presenting feature of Covid-19 in the young.N Engl J Med, 2020 May 14;382(20):e60. Doi: 10.1056/NEJMc2009787.

Guo T, Fan Y, Chen M, Wu X, Zhang L, Heet T, ET al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19).JAMA Cardiol, 2020 Jul 1;5(7):811-818. Doi: 10.1001/jamacardio.2020.1017.

Shi S, Qin M, Shen B, Cai Y, Liu T, Yanget F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol, 2020 Jul 1;5(7):802-810. Doi: 10.1001/jamacardio.2020.0950..

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost, 2020 May;18(5):1094-1099. Doi: 10.1111/jth.14817.

Barazzoni R, Bischoff SC, Breda J, Wickramasinghe K, Krznaric Z, Nitzan D, et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr, 2020 Jun;39(6):1631-1638. Doi: 10.1016/j.clnu.2020.03.022.

Thibault R, Seguin P, Tamion F, Pichard C, Singer P. Nutrition of the COVID-19 patient in the intensive care unit (ICU): a practical guidance. Crit Care, 2020 Jul19;24(1):447.Doi: 10.1186/s13054-020-03159-z.

Fowler AA, Truwit JD, Hite RD, Morris PE, et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients with Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019;322:1261–1270. doi: 10.1001/jama.2019.11825

Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health. 2020 Jun 20:S1876-0341(20)30531-1. doi: 10.1016/j.jiph.2020.06.021.

Zhang, L.; Liu, Y. Potential interventions for novel coronavirus in China: A systematic review. J. Med. Virol. 2020, 92, 479–490. [CrossRef]

T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, COVID-19 REHBERİ Antisitokin antiinflamatuar tedaviler koagulopati yönetimi https://covid19bilgi.saglik.gov.tr/depo/rehberler/covid-19-rehberi/COVID-19-REHBERI

Cao B, Wang Y, Wen D, Liu w, Wang j, Fan g, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med, 2020 May 7;382(19):1787-1799. Doi: 10.1056/NEJMoa2001282.

Mehta P, McAuley DF, Brown M,Sanchez E, Tattersall RS, Manson JJ, et al . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020 Mar 28;395(10229):1033-1034. Doi: 10.1016/S0140-6736(20)30628-0.

Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases ofCOVID-19. Lancet Infect Dis,2020Jun;20(6):656-657. Doi: 10.1016/S1473-3099(20)30232-2.

Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol,2020 Aug;2(8):e474-e484. Doi: 10.1016/S2665-9913(20)30173-9.

Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, et al. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmun Rev, 2020 Jul;19(7):102564. Doi: 10.1016/j.autrev.2020.102564.

Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol, 2012;42(2):145–153. Doi: 10.1007/s12016-010-8243-x.

55.Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med,2015;66:145-59. Doi: 10.1146/annurev-med-061813-012806.

56.Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol, 2020 May;20(5):269-270. Doi: 10.1038/s41577-020-0308-3.

57.Kaly L, Rosner I. Tocilizumab—a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol,2012 Feb;26(1):157-65. Doi: 10.1016/j.berh.2012.01.001.

58.Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A,2020 May 19;117(20):10970-10975. Doi: 10.1073/pnas.2005615117.

59.Rizk JG, Zadeh KK, Mehra MR, Lavie CJ, Rizk Y, Forthal DN.Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs, 2020 Jul 21 : 1–26.Doi: 10.1007/s40265-020-01367-z

60.Haga S, Yamamoto N, Nakai-Murakami C,Osawa Y, Tokunaga K, SataT, et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci USA,2008 Jun 3;105(22):7809-14. Doi: 10.1073/pnas.0711241105.